July 25, 2024Open Access

PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The study was designed to assess outcomes with once-daily oral semaglutide in adults with type 2 diabetes (T2D) naïve to injectable glucose-lowering agents, in Swedish clinical practice.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Catrina et al. (Thu,) studied this question.

synapsesocial.com/papers/68e5f0a2b6db64358758511f https://doi.org/https://doi.org/10.1007/s13300-024-01614-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study2024 · 37 citations
2Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022 · 991 citations
3Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial2017 · 580 citations
4International Diabetes Federation 20172018 · 13,553 citations
5Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden2020 · 26 citations

Me gusta

Guardar

Ver artículo completo